Industry Report! NK Cell Therapy: The Potential Dark Horse in the Next 100-Billion-Yuan Market
- Elva Chen
- 4 hours ago
- 4 min read
As medicine enters a new era of "cell therapy", a revolution subverting traditional diagnosis and treatment has arrived. Global clinical trials of cell therapy have exceeded 10,000 cases, with China evolving from a follower to a leader. NK cell immunotherapy is emerging as a dark horse, opening up a blue ocean in the 100-billion-yuan market. This wave of technological breakthroughs and market opportunities is reshaping the future landscape of human health.
Over 10,000 Global Projects Bear Witness:
Cell Therapy Enters a Golden Era of Development
Recently, a research team from Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology and Columbia University in the United States released a comprehensive analysis of global clinical research on cell therapy in the international journal Frontiers in Pharmacology.
The study conducted a full analysis of global cell therapy clinical trials, marketed products and regional regulatory trends up to October 2025, outlining the overall development and cutting-edge directions of the global cell therapy field, and providing an important reference for clinical translation and industrial development in this area.
As of October 2025, a total of 10,373 cell therapy clinical trials have been registered worldwide, distributed in major regions including the United States (3,563 trials), China (3,365 trials) and Europe (1,584 trials), forming a tripartite competitive pattern.
China launched its first cell therapy clinical trials in 2005 and has now become a global "hub for cell therapy trials". Since 2016, China has surpassed the United States in the number of cell therapy clinical trials, ranking first in the world. It has formed distinct technological advantages especially in core fields such as CAR-T, NK cells and mesenchymal stem cells.
Two Core Directions Dominate:
Cancer Treatment Becomes the Key Application Area
With its unique advantage as a "living biological drug", cell therapy has become one of the most revolutionary fields in modern medicine. Different from traditional small-molecule drugs and biological agents, living cells can cross biological barriers, precisely target diseased tissues, and treat diseases through multiple mechanisms such as attacking cancer cells, repairing damaged tissues and restoring physiological functions, showing irreplaceable value in oncology, autoimmune diseases, rare diseases and other fields.
At present, global cell therapy research mainly focuses on two directions: immune cell therapy and stem cell therapy, with 5,167 clinical trials for immune cell therapy and 4,796 for stem cell therapy.
In terms of indications, cancer treatment accounts for half of the market (56.1%), followed by immune system diseases (9.3%), and exploration in multiple disease areas such as cardiovascular, neurological and metabolic diseases is expanding continuously. The proportion of oncology research in China and the United States reaches 66.5% and 61.9% respectively, far exceeding the global average.
NK Cell Therapy:
The Potential Dark Horse in the Next 100-Billion-Yuan Market
In the immune cell therapy track, in addition to the outstanding performance of CAR-T which leads in the number of research projects, NK cell therapy is emerging with unique advantages and becoming a new growth point with great market potential.
China has seized the opportunity in the field of NK cell therapy, with the number of clinical trials exceeding that of the United States, making it a global core hub for NK cell research.
Unlike CAR-T therapy which is mainly concentrated in hematologic malignancies, NK cell therapy has broader application scenarios. It not only shows good prospects in the treatment of solid tumors such as lung cancer, liver cancer and colorectal cancer, but also has potential value in autoimmune diseases, neurological diseases and other fields, making up for the shortcomings of existing treatment methods.
From a market perspective, with the rising incidence of cancer and the upgraded demand for precision treatment among patients, the market space for NK cell therapy is expanding rapidly.
At present, the global cell therapy market is dominated by CAR-T, but NK cell therapy, relying on its potential of "off-the-shelf" (allogeneic use available without personalized preparation), breaks through the bottlenecks of CAR-T therapy such as "autologous preparation, high price and long preparation cycle", and becomes a more accessible immunotherapy option.
Industry insiders predict that with technological maturity and product launch, NK cell therapy will witness explosive growth in the next 5-10 years and become another 100-billion-yuan track following CAR-T.
Technology Empowers Health:
China's Cell Therapy Steps onto the World Stage
From the vigorous development of 10,000 global clinical trials, to China's independent technological innovations, and then to the potential burst of NK cell therapy, the golden age of cell therapy has arrived.
With comprehensive advantages including "the world's largest number of clinical trials, the continuous emergence of independent products, and a regulatory system in line with international standards", China is transforming from a "participant" in global cell therapy to a "rule-maker" and "technology leader".
In the future, cell therapy will extend from rare disease and cancer treatment to a wider range of disease areas, truly becoming an inclusive treatment method. As a potential rising star, NK cell therapy is expected to complement CAR-T therapy and jointly build a comprehensive ecosystem of immune cell therapy.
We have every reason to expect that in the near future, cell therapy will bring more miracles to human health.
Comments